Story Poster

Highly-touted offensive lineman Marcus Tate signs with Clemson

December 16, 2020
3,619

Feel the difference - The MOST DIGITAL CONTENT covering your CLEMSON TIGERS! Avoid clickbait and sites bloated with advertising! 


★★★★ Marcus Tate - 6-5, 315 - TRU Prep Academy, Miami Gardens, FL

Robbie Caldwell hauled in another offensive lineman today as 4-star Marcus Tate‍ officially signed with Clemson.

Tate originally had offers from Alabama, Auburn, Michigan, Penn State, Texas A&M, and many more. We will have more on Tate’s signing coming soon.

The 2021 class is shaping up to be another great one as the Tigers have secured signings from several players ranked inside ESPN’s Top 300.  

Overview: Ranked as the No. 112 overall player in the nation by Rivals.com, which also listed him as the 6th-best offensive guard in the nation and 18th-best player in Florida … ranked as the No. 132 overall player by ESPN.com, which also listed him as the 17th-best player at his position and 19th-best player in Florida … top 225 player according to 247Sports, which ranked him as the 12th-best offensive guard … ranked as a four-star by all services … committed to Clemson on Sept. 24, 2019 … played for Daniel Luque at NSU School in 2020, he played his first three years at University School … that school cancelled its 2020 season due to COVID19, so he played for Tru Prep Academy in 2020, where he was a member of the 2020 State Championship team … wore No. 55 in high school … Committed to Clemson on Sept. 24, 2019 … recruited by Brent Venables and Robbie Caldwell … plans to enroll at Clemson in January … born Jan. 31, 2003 and is the youngest member of Clemson’s 2021 signing class.

Reminds us of:

Jordan McFadden

Tags: Marcus Tate
Discussion from...

Highly-touted offensive lineman Marcus Tate signs with Clemson

3,566 Views | 0 Replies | Last: 3 yr ago by Staff Reports
There are not any replies to this post yet.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.